Facilitatory effect of huperzine-A on mouse neuromuscular transmission in vitro

Acta Pharmacologica Sinica

Volumn 17, Issue 4, 1996, Pages 299-301

  Lin, Jia Hui ^a   Hu, Guo Yuan ^a   Tang, Xi Can ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

cholinesterase inhibitors; diaphragm; E2020; electrophysiology; huperzine A; neuromuscular junction; phrenic nerve; tacrine

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; HUPERZINE A; TACRINE;

ANIMAL TISSUE; ARTICLE; CHOLINERGIC SYSTEM; DRUG EFFECT; ELECTROPHORESIS; ENDPLATE POTENTIAL; ENZYME INHIBITION; HEMIDIAPHRAGM; IN VITRO STUDY; MOUSE; MYASTHENIA; NEUROMUSCULAR SYNAPSE; NEUROMUSCULAR TRANSMISSION; NONHUMAN; PHRENIC NERVE;

ANIMALS; CHOLINESTERASE INHIBITORS; FEMALE; INDANS; MALE; MICE; NEUROMUSCULAR JUNCTION; PIPERIDINES; SESQUITERPENES; SYNAPTIC TRANSMISSION; TAURINE;

EID: 0029783741     PISSN: 02539756     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Coyle JT, Price DL, DeLong MR. Alzheimer's disease: a disorder of cortical cholinergic innervation. Science 1983; 219: 1184-90.
2. Becker RE, Moriearty P, Unni L. The second generation of cholinesterase inhibitors: clinical and pharmacological effects. In: Becker R, Giacobini E, editors. Cholinergic basis for Alzheimer therapy. Boston: Birkhauser, 1991: 263-96.
3. Rogers SL, Yamanishi Y, Yamatsu K. E2020 - the pharmacology of apiperidine cholinesterase inhibitor. In: Becker R, Giacobini E, editors. Cholinergic basis for Alzheimer therapy. Boston: Birkhauser, 1991: 314-20.
4. Wang YE, Yue DX, Tang XC. Anti-cholinesterase activity of huperzine A. Acta Pharmacol Sin 1986; 7: 110-3.
5. Tang XC, De Sarno P, Sugaya K, Giacobini E. Effect of huperzine A, a new cholinesterase inhibitor, on the central cholinergic system of the rat. J Neurosci Res 1989; 24: 276-85.
6. De Sarno P, Pomponi M, Giacobini E, Tang XC, Williams E. The effect of heptyl-physostigmine, a new cholinesterase inhibitor, on the central cholinergic system of the rat. Neurochem Res 1989; 14: 971-7.
7. Cheng YS, Lu CZ, Ying ZL, Ni WY, Zhang CL, Sang GW. 128 cases of myasthenia gravis treated with huperzine A. New Drugs Clin Remedies 1986; 5: 197-9.
8. Tang XC, Xiong ZQ, Qian BC, Zhou ZF, Zhang LL. Cognition improvement by oral huperzine A: a novel acetylcholinesterase inhibitor. In: Giacobini E, Becker R, editors. Alzheimer therapy: therapeutic strategies. Boston: Birkhauser, 1994: 113-9.
9. Xu SS, Gao ZX, Weng Z, Du ZM, Xu WA, Yang JS, et al. Efficacy of tablet huperzine-A on memory, cognition, and behavior in Alzheimer's disease. Acta Pharmacol Sin 1995; 16: 391-5.
10. Shi YL, Xu YF, Wang WP, Xu K, Guo M, Wang KY. Facilitatory effect of Pinellia ternata lectin on quantal release of acetylcholine from nerve terminals. Acta Pharmacol Sin 1992; 13: 513-6.
11. Fiekers JF. Interactions of edrophonium, physostigmine and methanesulfonyl fluoride with the snake end-plate acetylcholine receptor-channel complex. J Pharmacol Exp Ther 1985; 234: 539-49.
12. Kordas M. On the role of junctional cholinesterase in determining the time course of the end-plate current. J Physiol (Lond) 1977; 270: 133-50.
13. Thesleff S, Sellin LC, Tagerud S, Tetrahydroaminacridine (tacrine) stimulates neurosection at mammalian motor endplates. Br J Pharmacol 1990; 100: 487-90.
14. Canti C, Marti E, Marsal J, Solsona C. Tacrine-induced increase in the release of spontaneous high quantal content events in Torpedo electric organ. Br J Pharmacol 1994; 112: 19-22.